Quantitation of BCR::ABL1 p210 transcripts in peripheral blood of CML patients for diagnosis and monitoring.
Genetics - Molecular Oncology
3x EDTA (Lavender) dedicated to Genetics
Send to MONC
BCR/ABL1 Quantitative P210 PCR
CML Molecular Monitoring
t(9;22) P210 RQ-PCR
12 ml peripheral blood (bone marrow is not accepted for this assay)
Transport to the laboratory at ambient temperature within 72 hours of collection.
Transcripts resulting from the two major breakpoints, BCR::ABL1 e13a2 (b2a2) and e14a2 (b3a2), and an endogenous control gene ABL1 are amplified and results are expressed as a ratio percent (BCR::ABL1/ABL x 100) according to the International Scale (IS).
The significance of BCR::ABL1 transcript level should always be considered in the context of treatment and sequential BCR::ABL1 testing. A level at or below 0.1% (IS) indicates a major molecular response.
Lower Limit of Quantitation: at least 4.52 log molecular reduction (MR) from baseline, i.e. 0.003%(IS).
Please Note: This assay will only detect the two common BCR::ABL1 p210 transcripts. If a diagnostic sample is negative for BCR-ABL1 p210 transcripts by the Xpert BCR::ABL Ultra Assay we recommend that BCR::ABL1 testing by FISH is performed to exclude rarer BCR::ABL1 transcripts associated with CML/ALL.
Xpert BCR::ABL Ultra Assay, GeneXpert, Cepheid.
$575.12 (Exclusive of GST)
An additional charge of approximately $200 may be applied to samples received on weekends and public holidays for processing by on-call staff.
In the case of this test the cost will only be incurred if the sample will be older than 72 hours post collection by the next business day.
"*" indicates required fields